Cabaletta Bio is a clinical-stage biotechnology company developing engineered T-cell therapies for autoimmune disease. Its approach centers on chimeric autoantibody receptor (CAAR) T cells designed to selectively target B cells that produce disease-causing autoantibodies. The pipeline focuses on serious B cell–mediated conditions rather than broad immunosuppression.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -35.9 | — |
| Q2 2025 | 0 | — | -45.1 | — |
| Q3 2025 | 0 | — | -44.9 | — |
| Q4 2025 | 0 | — | -41.9 | — |
| Q1 2026 | 0 | — | -43.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Kyverna Therapeutics, Inc. (KYTX), Bankwell Financial Group, Inc. (BWFG), Rimini Street, Inc. (RMNI), Ovid Therapeutics Inc. (OVID), Tactile Systems Technology, Inc. (TCMD), AMC Global Media Inc. (AMCX)